Zhengye Biotechnology Holding Ltd Annual Report - How They Did This Year

I’m breaking down Zhengye Biotechnology’s performance to help you decide if this company fits your portfolio. Here is the plain-English guide to their recent results.

1. What does this company do?

Based in Jilin City, China, Zhengye Biotechnology researches, makes, and sells veterinary products, focusing primarily on vaccines for pigs. When you buy ZYBT shares, you are buying a Cayman Islands "holding company" that controls the Chinese operations through legal contracts, known as a Variable Interest Entity (VIE) structure.

2. Financial Performance

The company’s sales have trended downward over the last three years:

• 2023: RMB 211.7 million
• 2024: RMB 186.4 million
• 2025: RMB 116.4 million (about US$16.6 million)

The business relies heavily on swine vaccines, which accounted for 77.5% of their 2025 revenue. Because of this, the company’s financial health is closely tied to the ups and downs of the pig farming industry.

3. Major Wins and Challenges

The company faces a difficult environment. Their customers—livestock farmers—are currently managing high feed and fuel costs, leading them to reduce spending on preventative vaccines. Simultaneously, Zhengye faces intense competition and a shrinking pool of customers as smaller farms consolidate into larger, price-sensitive operations.

4. Financial Health

The company’s cash flow is sensitive to the payment cycles of their customers, who are also under financial pressure. A notable factor for investors is their lack of product liability insurance. Because they produce biological goods for animals, any significant legal claim could impact their available cash reserves.

5. Key Risks

Beyond the risks associated with the holding company structure, the business faces several specific operational dangers:

• Product Liability: If vaccines fail or cause illness, the company could be held responsible for livestock losses.
• Manufacturing Risks: Production is concentrated in specific facilities. Power outages, labor issues, or local disease outbreaks could halt production or force recalls.
• Research Uncertainties: While the company invests heavily in research, there is no guarantee these efforts will lead to successful products or government approval.
• "Off-Label" Use: If farmers use vaccines incorrectly, the company could face legal trouble and damage to its reputation.
• Animal Testing: The business model relies on animal testing. Shifts in regulations or public opinion could create hurdles for bringing new products to market.

6. Competitive Positioning

The market is crowded with both domestic and international rivals. Additionally, the company faces competition from "holistic" health products and the development of disease-resistant animals, both of which could reduce the long-term demand for traditional vaccines.

7. Leadership and Strategy

The company does not pay dividends, choosing instead to reinvest cash into research and operations. As a "foreign private issuer," they follow different reporting requirements than standard U.S. companies regarding executive pay and internal controls.

8. Future Outlook

Management has noted that past performance is not a guarantee of future results. With revenue in decline and the agricultural economy remaining volatile, the company’s future depends on its ability to diversify its product line beyond swine vaccines and stabilize its market share.

Investor Takeaway: Zhengye Biotechnology is currently navigating a period of shrinking revenue and high industry competition. When considering this stock, weigh the potential for a turnaround against the risks of their concentrated product line, the lack of liability insurance, and the complexities of the VIE structure.